Ultragenyx Pharmaceutical Inc. notified that On March 20, 2023 Lars Ekman, M.D., Ph.D. announced his decision to retire from the Board of Directors of the Company, effective immediately after the Company's 2023 Annual Meeting of Stockholders, currently scheduled for June 7, 2023. Dr. Ekman's decision to retire from the Board is for personal reasons and is not related to any disagreement with the Company or its management on the Company's operation, policies, or practices.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.05 USD | -9.44% | -5.68% | -18.34% |
Jun. 14 | Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $45 From $48, Keeps Neutral Rating | MT |
Jun. 14 | Sector Update: Health Care Stocks Lean Lower Pre-Bell Friday | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.34% | 3.53B | |
+18.15% | 124B | |
+18.02% | 112B | |
+5.07% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- RARE Stock
- News Ultragenyx Pharmaceutical Inc.
- Ultragenyx Pharmaceutical Inc. Announces Retirement of Lars Ekman as Board of Directors